Vibeke Andresens bilde

Vibeke Andresen

  • E-postvibeke.andresen@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations. American Journal of Hematology.
  • Vis forfatter(e) (2023). The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML? Leukemia.
  • Vis forfatter(e) (2023). Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood. 1846-1857.
  • Vis forfatter(e) (2023). Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Nature Communications.
  • Vis forfatter(e) (2022). The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. Leukemia. 1931-1934.
  • Vis forfatter(e) (2022). Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Research Square.
  • Vis forfatter(e) (2020). Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. Frontiers in Pharmacology.
  • Vis forfatter(e) (2020). Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines (. The FASEB Journal. 3774-3791.
  • Vis forfatter(e) (2018). Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. Scientific Reports. 1-17.
  • Vis forfatter(e) (2017). Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 7946-7963.
  • Vis forfatter(e) (2016). Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 8105-8118.
  • Vis forfatter(e) (2016). Human T cell leukemia virus type 1 infection of the three monocyte subsets contributes to viral burden in humans. Journal of Virology. 2195-2207.
  • Vis forfatter(e) (2016). Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
  • Vis forfatter(e) (2015). Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. ACS Chemical Biology. 855-863.
  • Vis forfatter(e) (2015). Identification of novel monocistronic HTLV-1 mRNAs encoding functional Rex isoforms. Retrovirology.
  • Vis forfatter(e) (2013). Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLOS ONE. 11 sider.
  • Vis forfatter(e) (2008). Functional rescue of an oligomerization-defective HIV-1 Rev mutant by fusion with an oligomeric tag. Archives of Virology. 357-362.
  • Vis forfatter(e) (2013). Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death and Differentiation. 1124-1124.
Brev til redaktøren
  • Vis forfatter(e) (2023). The NPM1 mutant defines AML irrespective of blast count. American Journal of Hematology.
  • Vis forfatter(e) (2017). Investigation of the intercellular structure tunneling nanotube (TNT) in leukemia.
  • Vis forfatter(e) (2012). Human oncogenic retrovirus HTLV-1 replication is suppressed by the MHC class II transcriptional activator CIITA via an inhibitory action on the viral transactivator Tax-1. Immunology. 639-639.
  • Vis forfatter(e) (2014). Cell-to-Cell Communication in Acute Myeloid Leukemia by Tunneling Nanotubes.
  • Vis forfatter(e) (2023). Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia (Nature Communications, (2023), 14, 1, (115), 10.1038/s41467-022-35624-4). Nature Communications.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2019). Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. The Cancer Journal. 153-163.
  • Vis forfatter(e) (2017). Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in medicine.
  • Vis forfatter(e) (2013). "Tunneling nanotube" nyoppdaget budbringer mellom celler. Bioingeniøren. 10-15.

Se fullstendig oversikt over publikasjoner i CRIStin.